阿斯利康AstraZeneca plc (AZN) 2011年年度报告「LSE」.pdf

1、AstraZeneca Annual Report and Form 20-F Information 2011Registered office and corporate headquartersAstraZeneca PLC2 Kingdom StreetLondon W2 6BDUKTel:+44(0)20 7604 8000Fax:+44(0)20 7604 8151Investor relationsEmail:UK:as aboveSweden:Investor RelationsAstraZeneca ABSE-151 85 SdertljeSwedenTel:+46(0)8

2、553 260 00Fax:+46(0)8 553 290 00US:Investor RelationsAstraZeneca Pharmaceuticals LP1800 Concord PikePO Box 15437WilmingtonDE 19850-5437USTel:+1(302)886 3000Fax:+1(302)886 2972RegistrarEquiniti Limited Aspect HouseSpencer RoadLancingWest Sussex BN99 6DAUKTel(freephone in the UK):0800 389 1580Tel(outs

3、ide the UK):+44(0)121 415 7033Swedish Central Securities DepositoryEuroclear Sweden ABPO Box 191SE-101 23 StockholmSwedenTel:+46(0)8 402 9000US DepositaryJPMorgan Chase&CoPO Box 64504St PaulMN 55164-0504USTel(toll free in the US):888 697 8018Tel(outside the US):+1(651)453 2128Email:Contact informati

4、onAstraZeneca Annual Report and Form 20-F Information 2011This Annual Report is also available on our website, connectsusallImproving health is one of the toughest challenges facing the world today.As a global biopharmaceutical company,AstraZeneca has a key contribution to make by providing innovati

5、ve medicines for some of the worlds most serious diseases.We know that if we are to deliver medicines that people really need and value,we cannot do it in isolation.We work closely with all our stakeholders to understand their needs and challenges.We are committed to acting with integrity and high e

6、thical standards in everything we do and our goal is always to improve health for patients and bring benefit for our stakeholders,our business and society.Important information for readers of this Annual ReportCautionary statement regarding forward-looking statementsThe purpose of this Annual Report